Laura Whitehouse Net Worth

The estimated Net Worth of Laura Whitehouse is at least 763 千$ dollars as of 28 February 2006. Laura Whitehouse owns over 10,000 units of Repligen stock worth over 753,854$ and over the last 20 years Laura sold RGEN stock worth over 8,758$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Laura Whitehouse RGEN stock SEC Form 4 insiders trading

Laura has made over 2 trades of the Repligen stock since 2005, according to the Form 4 filled with the SEC. Most recently Laura exercised 10,000 units of RGEN stock worth 12,500$ on 28 February 2006.

The largest trade Laura's ever made was exercising 10,000 units of Repligen stock on 28 February 2006 worth over 12,500$. On average, Laura trades about 3,206 units every 53 days since 2005. As of 28 February 2006 Laura still owns at least 5,257 units of Repligen stock.

You can see the complete history of Laura Whitehouse stock trades at the bottom of the page.

What's Laura Whitehouse's mailing address?

Laura's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453.

Insiders trading at Repligen

Over the last 22 years, insiders at Repligen have traded over 118,224,292$ worth of Repligen stock and bought 160,440 units worth 1,459,521$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Glenn P Muir、Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of 3,015,702$. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth 1,139,034$.

What does Repligen do?

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Complete history of Laura Whitehouse stock trades at Repligen

Repligen executives and stock owners

Repligen executives and other stock owners filed with the SEC include:

• Anthony Hunt,
  President, Chief Executive Officer, Director
• Jon Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Senior Vice President - Research and Development
• Anthony J. Hunt,
  CEO, Pres & Director
• Jon K. Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Sr. VP of R&D
• Karen Dawes,
  Independent Chairperson of the Board
• Glenn Muir,
  Independent Director
• Thomas Ryan,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Rohin Mhatre,
  Independent Director
• Carrie Eglinton,
  Director
• James Slaughter,
  Chief HR Officer
• James R. Bylund,
  Chief Operating Officer
• Christine Gebski,
  Sr. VP of Filtration & Chromatography
• Ken Elmer,
  Global Head of HR
• Rachel Goodrich,
  VP of Marketing
• Stephen Tingley,
  VP of Global Sales
• Squire Servance,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Sondra S. Newman,
  Global Head of Investor Relations
• Jim Bylund,
  Sr. VP of Operations & Information Technology
• Jason K Garland,
  CFO
• Glenn L Md Cooper,
  Director
• James R Rusche,
  Senior Vice President
• John Cox,
  Director
• Howard Benjamin,
  
• Roy T Eddleman,
  10% owner
• Christine Gebski,
  See Remarks
• G William Miller,
  Director
• Timothy Scott Harris,
  
• Barbara Burnim Day,
  Vice President
• Daniel W Muehl,
  CFO
• Partners L P/Ilbiotechnolog...,
  
• Alfred Lewis Goldberg,
  Director
• Walter C Herlihy,
  PRESIDENT, CEO
• Michael A Griffith,
  Director
• Daniel P Witt,
  Vice President
• Jonathan I Lieber,
  CFO
• Earl Webb Henry,
  Director
• William J Kelly,
  Vice President
• Alexander Rich,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Hal Landy,
  Vice President
• Paul Schimmel,
  Director
• Laura Whitehouse,
  Vice President
• Robert J Hennessey,
  Director
• Margaret Pax,
  
• Konstantin Konstantinov,
  
• Martin D Madaus,
  
• James Bylund,
  Chief Operating Officer
• Olivier Loeillot,
  Chief Executive Officer